Encysive jumps 17% on higher Thelin guidance
Shares in the USA's Encysive Pharmaceuticals jumped 17.3% to $0.95 on December 14 after the firm announced that full-year 2007 sales of its hypertension drug Thelin (sitaxentan sodium) would be better than forecast.
Encysive will report its fourth-quarter 2007 results on March 5, 2008, at which time it expects full-year 2007 revenues from the drug in the range of approximately $10.5 million to $11.5 million. The US biotechnology firm expects to record sales of Thelin for 2008 in the region of between $40.0 million and $50.0 million.
The agent is the first selective endothelin A receptor antagonist, and the first once-daily oral treatment available for patients with pulmonary arterial hypertension in the European Union.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze